Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. Emergency Medicine (Paediatric)
  6. Epstein-Barr virus (EBV) guidance, paediatrics (126)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Epstein-Barr virus guidance, paediatrics (126)

Warning

Objectives

Investigation and destination for the management of EBV - primary care follow-up, secondary care follow-up or hospital admission.

Scope

Children presenting with suspected or confirmed EBV. 

Audience

Medical and nursing staff who see acutely unwell children and young people.  

Epstein-Barr virus is a common infection in childhood which, in the large majority of cases, is experienced as a mild/sub-clinical infection. However, in a small minority of cases, it can produce life threatening complications; even in children previously assumed to be immunocompetent.

Acute EBV infection can cause aseptic meningitis, encephalitis, hepatitis, myocarditis, orchitis, cytopenias, lymphoproliferation and splenic rupture.

The glandular fever screening test is useful if positive in adolescents, but often gives a false negative result in younger children with EBV infection. EBV IgM should therefore be used for diagnosis of acute infection. EBV IgG indicates past exposure, and may therefore not distinguish between past and current infection. Plasma EBV PCR should not be requested routinely in the immunocompetent. Its use is restricted to severely unwell patients in PICU and the immunocompromised.

In a child where a diagnosis of EBV has been made and who presents to hospital with compatible clinical symptoms, the following minimum investigations should be undertaken:

  • Full Blood Count
  • Urea and electrolytes
  • Liver Function Tests
  • Any other investigations deemed clinically appropriate

If evidence of EBV induced anaemia, leucopenia, thrombocytopenia, deranged liver function tests, significant splenomegaly or organ dysfunction is found on clinical assessment, then the child should be discussed with, and follow-up arrangements made by the receiving general paediatric consultant.

If a child without abnormal signs/investigations is deemed well enough to go home, then GP follow-up within a week is advised.

If a child is assessed to be unwell enough to warrant admission as a result of EBV infection, the paediatric ID team should be consulted.

For further clinical advice contact the paediatric ID service 0141 452 4939 or via switchboard out of hours

Suspected EBV and Confirmed EBV flowchart

 

Editorial Information

Last reviewed: 24/01/2022

Next review date: 31/01/2025

Author(s): Rosie Hague.

Version: 5

Author email(s): rosie.hague@ggc.scot.nhs.uk.

Approved By: Paediatric Clinical Effectiveness & Risk Committee